Returning to London for its landmark sixth year, the must-attend Pharma Integrates event will take place on 15-16 November at the Grange City Hotel, London. Supported in 2016 by in excess of 70 prestigious speakers and 300 senior industry executives, a top-tier programme of interviews and interactive debate led panel discussions in 2017 will focus on the strategic issues facing the drug manufacturing sector and, once again, play a vital role in shaping pharma’s future. Key themes and topics for 2017 will be released shortly.

Pharma Integrates 2016 tackled issues such as the rise of precision medicine, disruptive thinking in pharmaceutical regulation, improving patient compliance, future pharmaceutical supply chains and more.

The speakers, delegates and sponsors of Pharma Integrates are developers and manufacturers of pharmaceutical and biopharmaceutical products, speciality chemicals, bulk products and raw materials, drug delivery devices, instrumentation and equipment. They also work in universities, research institutes, government agencies, contract research and manufacturing companies, and organisations involved in consultation and market research, finance, regulatory affairs, information technology and patient advocacy.

AGENDA (2016)






13:45 – 14:05 Welcome
and opening remarks

Mike Thompson, Chief Executive, ABPI

Topics to be discussed during the interview with Professor Sir John Bell include the current status of personalised medicine, understanding the use of “Big Data”, UK’s position in collaborative research following Brexit and the strategic coordination of research between NIHR and MRC. The interview will be conducted by Trevor Jones CBE.

Citing examples from different therapeutic areas, such as hepatitis C, Alzheimer’s and antibiotics, this session will discuss new development, finance and reimbursement strategies for the pharmaceutical industry. Panellists will focus on topics including moving from a product supplier model to a paid by results scenario, the NGO approach to meeting unmet medical needs, the honest truth about mergers and acquisitions and the disintermediation of the current healthcare pathway.

Facilitated by:

Andy Black Founder & Board Director, Kinapse

Panellists include:

Mike Rea, Chief Executive Officer, IDEA Pharma
Harry Stratford Non-Executive Director, Neurocentrx
Richard Seabrook Head of Business Development Innovations, The Wellcome Trust
Rob Smith Vice President Product Development, Drug Delivery Solutions Europe, Catalent Pharma Solutions
Lukas Utiger, President, Drug Substance, Patheon


This session will focus on improving R&D performance to deliver better medicines for patients at a fraction of the time and $2bn cost currently associated with bringing a new drug to market.  Novel technologies such as human organs-on-chips, computational biology, artificial intelligence, in silico modelling and predictive drug design hold the promise for more fruitful drug discovery. Meanwhile, biomarkers for precision medicine and adaptive clinical trials design could revolutionise drug development. Panellists will discuss how industry needs to assume its own risk — rather than being managed by regulators — and new technologies and processes can be used to streamline groaning workflows. Other issues, such as how partnerships between patient advocacy groups, the implications of moving from primary care models to speciality care, insurers and payers, healthcare providers, big pharma, biotechs and academia might improve R&D productivity to the benefit of all stakeholders are also up for debate.

Facilitated by:

Jo Pisani Partner Pharmaceuticals & Lifesciences, Strategy& PricewaterhouseCoopers

Panellists include:
Andy Jones Vice President Pharmaceutical Innovation, AstraZeneca
Duncan McHale Vice President Global Exploratory Development, UCB Pharma
Chas Bountra Chief Scientist (SGC) & Professor of Translational Medicine, University of Oxford
David Hughes Chief Technology Officer CN BioInnovations

Topics to be discussed during the interview with Professor Guido Rasi include the future of the EMA after Brexit, data sharing and confidentiality, regulatory harmonization and the involvement of patients during drug development. This interview will be conducted by Tevor Jones CBE.



DAY 2: 08:30 START – 17:00 CLOSE




08:30 – 08:55 COFFEE & PASTRIES

Big pharmaceutical companies have painted themselves into a corner. By dropping products once out-of-patent protection and embarking on the wholesale divestment of skilled people and facilities that are crucial to developing properly differentiated products, there is nowhere left to go. So, what is pharmaceutical addiction and what’s the solution? The session will focus on driving down drug development costs, using in silico/ex vivo technologies to dramatically reduce attrition, the benefits of engaging deeply with healthcare professionals and patients, and moving to a production system approach for commercial supply.

Facilitated by:

Jesús Zurdo Senior Director Strategic Innovation, Lonza Pharma & Biotech

Panellists include:

Andy Jones Vice President Pharmaceutical Innovation, AstraZeneca
Gary Acton Captain, Pirates of Oncology
Graham Cox Principal Consultant, Kasocio
Rob Smith Vice President Product Development, Drug Delivery Solutions Europe, Catalent Pharma Solutions

In a world in which we need to collaborate in groups to be successful as individuals, understanding how to engage with small and large companies, with institutions and patient advocacy organisations has become increasingly important. But it’s not easily done. Despite the non-silo thinking, there are still hurdles to the adoption of new innovative practices and technologies. Is Big Pharma unable to adopt new practices and techniques because of its existing infrastructure? What lessons can we learn from more agile, rapidly growing companies? What can biotech companies learn from Big Pharma — and vice versa — that can be adapted to their specific environments to foster an atmosphere of more liberal thinking?

Facilitated by:

Maureen Coleman Executive Chairman, CN BioInnovations

Panellists include:

Nigel Blackburn Director of Drug Development, Centre for Drug Development, Cancer Research UK
Sylvia Lobo Established Products EU Regulatory Cluster Lead, Pfizer
Jonny Ohlson Chief Executive Officer, Touchlight Genetics
Matthew Hanson Global Head of API Contract Services & Manufacturing Franchise, Merck KGaA


Tackling a wide range of related topics, including patient monitoring, the role of medical devices and drug-device regulation, smart packaging and mHealth, the integration of medical technologies and linking diagnostics to drugs, the panel will address the overriding question of who provides this integrated service to customers in global markets. Is it a direct to patient model, which may be subject to regulatory constraints, and does it rely on channel partners, possibly creating local integration hurdles? Other challenges facing bringing diagnostics to market, such as data, investment and payment, are also up for debate.

Facilitated by:

Piers Mahon Director of Global Alliances, Cancer Commons

Panellists include:

Neil Mesher Chief Executive Officer, Philips UK & Ireland
Hakim Yadi Chief Executive Officer, Northern Health Science Alliance
Virginia Acha Executive Director – Research, Medical & Innovation, The Association of the British Pharmaceutical Industry (ABPI)
Professor Sue Hill OBE Chief Scientific Officer, NHS England


Improving the rate of uptake of innovation is a win-win situation for industry, government, health systems and, most importantly, patients, and several examples exist across the EU and US with the UK’s Accelerated Access Review, the EU’s PRIME and breakthrough designation in the US.

The panel will discuss whether accelerated access systems could be used to test both new technologies and new business models, how they can help to establish specific countries as a destination for pharma/life sciences innovation and, within the UK, what else can industry do to help the government enable the UK to become a world leader in innovation use to deliver significantly better outcomes for NHS patients at an affordable cost.

The panel will also consider the implications of suppliers to the pharmaceutical industry managing more uncertainty over launch dates and product volumes, cross-border deal making and multinational clinical studies.

Facilitated by:

Jo Pisani Partner Pharmaceuticals & Lifesciences, Strategy& PricewaterhouseCoopers

Panellists include:

James Xue Chairman and Chief Executive Officer, CANbridge Life Sciences
Mike Capaldi Chief Executive Officer, Sunergos Innovations
Mohit Misra Chief Medical Officer & Vice President Health Systems, Aetion
Amanda Begley Director of Innovation and Implementation, UCLPartners
Gino Martini Innovation & Outreach Lead, Roche Pharmaceuticals

Considering the impact of non-responders, non-adherence and non-refillers, the panel will assess what actually constitutes “non-compliance” and whether or not 25% compliance levels are acceptable for both the industry and patients. The role of smart medicine, payers and devices that can demonstrate compliance will be discussed, as will whether the pharmaceutical industry should invest in behavioural models for compliance/concordance … or whether that’s a topic for provider groups to consider.

Facilitated by:

Tina Flatau Managing Director, Medannex & OncoBioPharm

Panellists include:

Marco Mohwinckel Global Head Janssen Solutions & Janssen Healthcare Innovation, Janssen
Jon-Paul Sherlock Director, Intelligent Pharmaceutical (Respiratory), AstraZeneca
Louise Righton Global Marketing Operations Manager, 3M Drug Delivery Systems
Yury Rozenman Director Business Development, Qualcomm Life
Mark Duman Director of Market Development & Non-Executive Director Intelesant & Patient Information Forum



08:30 – 08:55 COFFEE & PASTRIES

What does the pharmaceutical industry really need, in terms of size, shape and scope from its supply chain, and why is the drug manufacturing sector still investing significantly in capacity when other industries no longer consider this to be a core capability? Topics for debate include how changes in drug production (smaller applications, niche therapies and global supply needs) impact the supply chain, M&A and consolidation, in-house versus outsourced production and whether manufacturing innovation and technologies such as continuous processing or late-stage customization should be driven by pharmaceutical manufacturers or the supplier base. Also on the agenda will be pharma’s service-oriented mindset, out-licensing dossiers to expedite product implementation and comparing pure CMOs with pharma companies offering contract manufacturing services.

Facilitated by:

Howard Marriage Translator and Entrepreneur in Residence, The Francis Crick Institute

Panellists include:

Gregor Kawaletz Chief Commercial Officer, IDT Biologika
Andy Dwyer Head of Clinical Packaging Operations, Target to Patient Supply Chain, GlaxoSmithKline
Lukas Utiger President, Drug Substance Patheon
Torsten Mau Corporate Vice President Supply Network and Process Management, Boehringer Ingelheim

  • Evolving business models… Opportunism or Identity crisis?

As companies seek to grow and optimise costs there are fewer pure play CMOs, CROs, Generic Cos and even Pharma Cos, the lines have blurred. The business models (and mindsets?) are different – is it a good thing?

  • Consolidation: Is bigger better?

The market is still hugely fragmented in both CDMOs as well as Pharma Cos, consolidation is taking place – what will it mean?

  • Ever changing needs

The nature of the products in development are evolving; lower volumes; faster timeframes; increased complexity; specialised technologies; costs of compliance and make versus buy decisions….. What does the future hold?

Facilitated by:

Mark Cassidy President API Services, Piramal Healthcare

Panellists include:

Ian Muir Managing Director, Aesica Pharmaceuticals
Michael Quirmbach Vice President, Global Sales & Marketing, CordenPharma International
David Long Head of Pharma Centre of Expertise and Business Excellence, UCB Pharma
John Fowler Division Director, Johnson Matthey Fine Chemicals


We’re increasingly hearing about patient centricity in pharma. It’s easier to see how this works in supporting patients to take medicines, but how does patient centricity affect the current pharmaceutical supply chain and manufacturing model? What can we learn from the automotive industry, for example, wherein customers configure requirements and pull requirements from the supply chain? Other sectors, such as food and beverage, FMCGs, etc., provide inspiration for customer-centric product design, which could be incorporated into the pharmaceutical business model. The panel will discuss push versus pull dynamics and whether the current system can be more closely aligned with other consumer-based consumption and lifestyle paradigms.

Facilitated by:

Mark Duman Director of Market Development & Non-Executive Director Intelesant & Patient Information Forum

Panellists include:

Gregor Anderson Device & Packaging Design Director, GlaxoSmithKline
Massimo Bresciani Executive Director Scientific Operations & Board Member, Research Centre for Pharmaceutical Engineering & Geriatric Medicines Society
Ben Reason Founding Partner & Director, Livework
Bev Nicol Senior Manager, Clinical Supplies Organisation, Pfizer Global Research & Development
Mark Phillips, Chairman, Cognetivity


The future pharmaceutical industry will require a connected health ecosystem comprising leaders from the entire healthcare spectrum, including medical device manufacturers, health service providers, pharmaceuticals, payers, application developers and more. The connected health model uses technology to provide remote healthcare that both maximises available resources and provides increased opportunities for consumers to engage with clinicians and better self-manage their care. Encompassing telehealth, data collection and analysis, remote home care and disease and lifestyle management, seamless connectivity, care co-ordination and patient engagement will enable increased efficiencies, reduced costs and improved patient health outcomes. The panel will discuss how the connected health model could address many inefficiencies (work flow management, chronic disease management and patient compliance) and propelling healthcare into the future.

Facilitated by:

Lizzie Tuckey Medical Director, Bupa UK

Panellists include:

Thom Van Every Executive Director ‘Hive’ Innovation Unit, ViiV Healthcare
Nicola Perrin Head of Policy, Wellcome Trust
Iain Buchan Professor of Public Health Informatics, University of Manchester & Director, Farr Institute
Matthew Bonam Director Intelligent Pharmaceuticals, AstraZeneca

Serialisation changes how the pharmaceutical industry makes and distributes medicines. Key topics on the agenda for debate include legal issues (FMD, DSCSA) and other key drivers, factors such as process change, equipment requirements, business issues and costs, and data (generation, storage, sharing, ownership and exploitation). Serialisation could also prove to be a key enabling technology for the industry, so the panel will also explore opportunities in smart packaging and eHealth (linking diagnostics, treatments and patient outcomes) and future supply chain issues, including late stage customization, the micro-manufacture of patient-specific drugs and distributed manufacturing locations.

Facilitated by:

Mark Davison Chief Executive Officer, Blue Sphere Health

Panellists include:

Martin FitzGerald Deputy Director General, GIRP – European Healthcare Distribution Association
Neil Lawrence Global Serialisation Champion, Global Manufacturing and Supply, GlaxoSmithKline
Paul Cruise Head of External Packaging EMEA and APAC, Shire Pharmaceuticals
Erik Haeffler Vice President Manufacturing Services & Head of CSR, Recipharm


Driven by an ageing population, globalisation and urbanisation, the level of change in the next 5 years will be greater than the pharmaceutical industry has experienced in the previous 35. A seismic shift is coming that will, for the unprepared, make existing 3-5 year plans redundant. Falling profit margins, greater operating costs, volatile demand forecasts, supply chain disruption, material and people shortages, etc., will have multiple repercussions, and only the resilient will survive. Those who are productively paranoid and have prepared their organisations to become resilient, adopted intelligent risk management and taken their overly complex legislation, systems and procedures back to basics will thrive and prosper. But what are these challenges and how should industry prepare? Let’s start the debate.

Facilitated by:

Martin Lush President, NSF Health Sciences Pharma Biotech Consulting

Panellists include:

Gino Martini Innovation and Outreach Lead, Roche Pharmaceuticals
Stephen Brewis Chief Research Scientist, BT Innovate & Design
Martin Price Vice President Health Economics, Market Access and Reimbursement, Janssen Europe, Middle East and Africa
Martin Gibson Chief Executive Officer & Director, NWEH & Greater Manchester NIHR Clinical Research Network
Catherine Geyman Director, Intersys



Pharma Integrates 2016 was a resounding success, in excess of 70 speakers contributed on the day.

View All Speakers


Pharma Integrates would like to thank our 2016 sponsors

View 2016 Sponsors


Book your ticket to Pharma Integrates 2017 today

Package includes:

  • Access to the full programme of conference interviews and panel debates (both days)
  • Champagne and canapé reception
  • Networking luncheon and refreshment breaks
  • Pre-event and on-site access to the mobile event networking app
  • Access to all filmed content post event

Book now to secure our early bird delegate rate of £995 + VAT.

Simply complete the form here and a representative will contact you or call us on +44 (0) 20 8688 3906 or +44 (0) 20 8667 9551.

Discounts are also available for multiple places for a limited period.



Pharma Integrates 2017 will be held on Wednesday 15th and Thursday 16th November, 2017 at the Grange City Hotel, London.

The Grange City is a luxury hotel in London near the River Thames, commanding sweeping views over the Tower of London and the iconic Tower Bridge. Reflecting its historic City location, the hotel site incorporates the last remaining section of London’s Roman Wall – which stands undamaged from when it was originally patrolled by Roman sentries.

Popular local attractions close to the hotel in the City of London include the Tower of London, Petticoat Lane Market, and St Katharine Dock.

The nearest underground station is Tower Hill, on District and Circle lines. When you exit the station, turn right and walk along Coopers Row for 50 metres: the hotel is on the right. The DLR Tower Gateway is 2 minutes away.

Special rates for Pharma Integrates 2017 are available. To book your discounted accommodation now please call +44 (0) 207 863 3700 or email Reservations quoting reference CCT169069 to secure a discounted rate.


8-14 Cooper’s Row,

Phone: +44 (0) 20 7863 3700

View Map


Pharma Integrates 2016 is supported by an 18 strong committee of recognised industry experts and leading practitioners


View The Committee


Pharma Integrates 2016 is supported by the following Partners

View All Partners


For all Speaker, Partner, Sponsor & Delegate Enquiries call Pharma Integrates on +44 (0) 20 8667 9551 or +44 (0) 20 8688 3906

Book now to secure our early bird delegate rate of £995 + VAT. The delegate package includes access to the full programme of conference interviews and panel debates, champagne reception, networking luncheon, refreshment breaks and access to all filmed content post event. Simply complete the form below and a representative will contact you shortly. Discounts are also available for multiple places for a limited period.

Alternatively, please leave your details in the form below.